Lumida
/TARS
⌘K
Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc

TARS
$59.85USD↑+3.74%+2.16 today

MARKET CAP

2.6B

P/E (TTM)

—

FWD P/E

149.2x

DAY RANGE

$57 – $60

52W RANGE

$39
$85

AI Summary

Stalk
Sell NowMedium

TARS remains in a Stage 4 decline with price well below major EMAs. A recent relief rally toward the 9/21 EMA zone has been capped, offering a tactical sell opportunity. No clear exhaustion or reversal signal has emerged despite extreme oversold readings. Medium-term structure stays bearish, and execution favors selling into rallies at dynamic resistance. A sustained close above the EMAs would invalidate this bearish stance.

  • ↑Q1 2026 Xtemvi net sales $145.4 M (+85% YoY) driven by DTC campaign and physician uptake.
  • ↑Full-year 2026 Xtemvi sales guidance $670–700 M implies continued robust demand.
  • ↓Culper short report alleges illegal Medicare copay assistance, raising regulatory scrutiny.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is an innovative biopharmaceutical company focused on developing therapies for conditions related to eye care, particularly through its flagship product, Xtemvi, an FDA-approved treatment for Demodex blepharitis affecting millions of Americans. Tarsus is actively expanding its presence in the ocular market by enhancing treatment paradigms while addressing significant unmet needs with a robust pipeline including candidates for ocular rosacea and Lyme disease prevention.

Bull says

  • ↑Q1 2026 Xtemvi net sales $145.4 M (+85% YoY) driven by DTC campaign and physician uptake.
  • ↑Full-year 2026 Xtemvi sales guidance $670–700 M implies continued robust demand.
  • ↑~50% of targeted eye‐care physicians prescribe Xtemvi weekly; retreatment steady at ~20%.
  • ↑Pipeline for ocular rosacea and Lyme‐prevention (TPO5) on track with early-phase data in 2027.
  • ↑High institutional ownership underpins research-backed confidence in growth.
  • ↑$418 M cash end-Q1 offers financial flexibility for marketing and R&D.

Bear says

  • ↓Culper short report alleges illegal Medicare copay assistance, raising regulatory scrutiny.
  • ↓Negative earnings yield and weak book-to-price metrics suggest potential overvaluation.
  • ↓Critical TPO4/TPO5 trials pose execution risk; delays could stall new revenue.
  • ↓Competition from Allergan, Novartis, Gilead may erode Xtemvi market share.
  • ↓Insider sales of $58.4 M could signal management’s concerns on near-term stock.
  • ↓Negative profitability and weak momentum factors indicate challenges sustaining gains.

Investment themes with TARS

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026bullish

Transcript signals

Bull points

  • In the first quarter of 2026, XtemV delivered more than $145 million in net product sales, an increase of more than 85% year-over-year, reflecting consistent patient outcomes and expanding eye care physician, or ECP, utilization across their practices.
  • Having spent time in the field and at several medical conferences over the past few months, I can tell you what we're hearing directly from ECPs. They describe Extenvi as one of the most impactful medicines they've ever used with consistent outcomes, clear utility across their practices, and broad access that is nearly universal.
  • We are deliberately building Tarsus to create and lead new categories in iCare and beyond with the pipeline and playbook to do it repeatedly.

Bear points

  • our base case is that we'd have to conduct a large vaccine like phase three, and that's something we'd have clarity around as we got ready for that and talk to potential partners.
Read full transcript analysis ›